NCT00717262View on ClinicalTrials.gov

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

September 30, 2008

Conditions
Healthy
Interventions
DRUG

HQK-1001

HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.

DRUG

placebo

Matching placebo capsules administered once a day, orally, for 14 days.

Trial Locations (1)

98403

Charles River Clinical Services Northwest, Tacoma

Sponsors
All Listed Sponsors
lead

HemaQuest Pharmaceuticals Inc.

INDUSTRY